The role of laboratory in ensuring appropriate test requests

Clinical Biochemistry

Volumn 50, Issue 10-11, 2017, Pages 555-561

  Ferraro, Simona ^a   Panteghini, Mauro ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL AUDIT; CLINICAL LABORATORY; CLINICAL PATHWAY; COMPUTERIZED PROVIDER ORDER ENTRY; COOPERATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY PERSONNEL; LABORATORY TEST; MONITORING; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; COST; ECONOMICS; ELECTRONIC MEDICAL RECORD SYSTEM; LABORATORY TECHNIQUE; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; STANDARDS;

ALGORITHMS; CLINICAL LABORATORY TECHNIQUES; COSTS AND COST ANALYSIS; HUMANS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PRACTICE GUIDELINES AS TOPIC;

EID: 85015801707     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2017.03.002     Document Type: Review

References (61)

1. Ferraro, S., Braga, F., Panteghini, M., Laboratory medicine in the new healthcare environment. Clin. Chem. Lab. Med. 54 (2016), 523–533.
2. Smellie, W.S., Appropriateness of test use in pathology: a new era or reinventing the wheel?. Ann. Clin. Biochem. 40 (2003), 585–592.
3. Hauser, R.G., Shirts, B.H., Do we now know what inappropriate laboratory utilization is? An expanded systematic review of laboratory clinical audits. Am. J. Clin. Pathol. 141 (2014), 774–783.
4. Lundberg, G.D., The need for an outcomes research agenda for clinical laboratory testing. J. Am. Med. Assoc. 280 (1998), 565–566.
5. Plebani, M., Panteghini, M., Promoting clinical and laboratory interaction by harmonization. Clin. Chim. Acta 432 (2014), 15–21.
6. Chassin, M.R., Galvin, R.W., The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. J. Am. Med. Assoc. 280 (1998), 1000–1005.
7. Epner, P.L., Gans, J.E., Graber, M.L., When diagnostic testing leads to harm: a new outcomes-based approach for laboratory medicine. Br. Med. J. Qual. Saf. 22:Suppl. 2 (2013), ii6–i10.
8. Cornes, M.P., Church, S., van Dongen-Lases, E., Grankvist, K., Guimarães, J.T., Ibarz, M., et al. The role of European Federation of Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase in standardization and harmonization of the preanalytical phase in Europe. Ann. Clin. Biochem. 53 (2016), 539–547.
9. Zhi, M., Ding, E.L., Theisen-Toupal, J., Whelan, J., Arnaout, R., The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One, 8, 2013, e78962.
10. Plebani, M., Panteghini, M., Harmonization in Laboratory Medicine: towards a global vision. Biochim. Clin. 39 (2015), 12–14.
11. Lippi, G., Banfi, G., Church, S., Cornesa, M., De Carli, G., Grankvista, K., et al. Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM)Working group for Preanalytical Phase (WG-PRE). Clin. Chem. Lab. Med. 53 (2015), 357–370.
12. The NHS Atlas of Variation in Diagnostic Services. Available at www.rightcare.nhs.uk/index.php/atlas/diagnostics-the-nhsatlas-of-variation-in-diagnostics-services (Accessed December 2016).
13. Salinas, M., López-Garrigós, M., Tormo, C., Uris, J., Primary care use of laboratory tests in Spain: measurement through appropriateness indicators. Clin. Lab. 60 (2014), 483–490.
14. Salinas, M., López-Garrigós, M., Flores, E., Uris, J., Leiva-Salinas, C., Requests of laboratory tests for the diagnosis and management of calcium-phosphate disorders in Spain. Rev. Med. Chil. 144 (2016), 990–997.
15. Schulenburg-Brand, D., Kumar, N., Zouwail, S., The impact of local guidelines on the tumour marker requesting patterns of a General Surgery Department. Ann. Clin. Biochem. 50 (2013), 438–442.
16. Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26 (2005), 1115–1140.
17. Hammerer-Lercher, A., Collinson, P., van Dieijen-Visser, M.P., Pulkki, K., Suvisaari, J., Ravkilde, J., et al. Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE). Clin. Chem. Lab. Med. 51 (2013), 1301–1306.
18. Appleby, J., Raleigh, V., Variations in Health Care – The Good, the Bad & the Inexplicable. 2011, The King's Fund http://www.kingsfund.org.uk/audio-video/john-appleby-variations-health-care (Accessed December 2016).
19. Callen, J., Georgiou, A., Li, J., Westbrook, J.I., The safety implications of missed test results for hospitalised patients: a systematic review. Br. Med. J. Qual. Saf. 20 (2011), 194e–1199.
20. Fryer, A.A., Smellie, W.S., Managing demand for laboratory tests: a laboratory toolkit. J. Clin. Pathol. 66 (2013), 62–72.
21. Ferraro, S., Panteghini, M., Laboratory medicine as the science that underpins medicine: the “high-sensitivity” troponin paradigm. Clin. Chem. Lab. Med. 53 (2015), 653–664.
22. Panteghini, M., Cardiac: is this biomarker ready for the prime time?. Scand. J. Clin. Lab. Invest. 70:Suppl. 242 (2010), 66–72.
23. Aakre, K.M., Langlois, M.R., Watine, J., Barth, J.H., Baum, H., Collinson, P., et al. Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. Clin. Chem. Lab. Med. 51 (2013), 1217–1226.
24. Panteghini, M., Belloni, A., Botta, M., Dominici, R., Luraschi, P., Magenta, M., et al. Strategie per l'impiego ottimale dei biomarcatori cardiaci: raccomandazioni e protocolli operativi. Biochim. Clin. 29 (2005), 419–428.
25. Panteghini, M., Piazza, E., Dolci, A., Scapellato, L., Luraschi, P., Strategie per l'impiego ottimale dei biomarcatori in oncologia: raccomandazioni e protocolli operativi. Biochim. Clin. 30 (2006), 210–223.
26. Dolci, A., Scapellato, L., Infusino, I., Panteghini, M., Results of the implementation of recommendations for appropriate use of tumor biomarkers (TBM) in a university hospital. Clin. Chem. Lab. Med., 45, 2007, S343.
27. Ferraro, S., Mozzi, R., Panteghini, M., Tumor marker ordering: do not lose control: a prospective clinical trial. Am. J. Clin. Pathol. 144 (2015), 649–658.
28. Liguori, G., Belfiore, P., D'Amora, M., Liguori, R., Plebani, M., The principles of Health Technology Assessment in laboratory medicine. Clin. Chem. Lab. Med. 55 (2016), 32–37.
29. 12 in serum: recommendations for test request and result interpretation. Biochim. Clin. 38 (2014), 326–329.
30. Szoke, D., Dolci, A., Russo, U., Panteghini, M., Determination of plasma homocysteine: recommendations for test requesting. Biochim. Clin. 38 (2014), 234–237.
31. 12 testing using the health technology assessment approach. Clin. Chem. Lab. Med. 52 (2014), 767–777.
32. Ferraro, S., Panzeri, A., Panteghini, M., Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays, and health outcomes. Clin. Chem. Lab. Med., 2016 Dec 19, 10.1515/cclm-2016-0804 (pii: /j/cclm.ahead-of-print/cclm-2016-0804/cclm-2016-0804.xml) (Epub ahead of print).
33. Wu, A.H., Folate testing: time to retire your VCR. JAMA Intern. Med. 174 (2014), 1697–1698.
34. Dominici, R., Dolci, A., Valente, C., Infusino, I., Panteghini, M., One-year audit of the implementation of protocols for optimal use of cardiac biomarkers in an Italian university hospital. Clin. Chem. Lab. Med., 45(supp l), 2007, S229.
35. Collinson, P., Hammerer-Lercher, A., Suvisaari, J., Apple, F.S., Christenson, R.H., Pulkki, K., et al., on behalf of the Working Group for Cardiac Markers, European Federation of Clinical Chemistry and Laboratory Medicine, How well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE). Clin. Chem. 62 (2016), 1264–1271.
36. Castaldo, G., The “famous pairs” in laboratory medicine. Biochim. Clin. 38 (2014), 307–313.
37. Salinas, M., Lopez-Garrigos, M., Uris, J., Pilot group of the Appropriate Utilization of Laboratory Tests (REDCONLAB) Working Group. Differences in laboratory requesting patterns in emergency department in Spain. Ann. Clin. Biochem. 50 (2013), 353–359.
38. Xu, Q., Higgins, T., Cembrowski, G.S., Limiting the testing of AST: a diagnostically nonspecific enzyme. Am. J. Clin. Pathol. 144 (2015), 423–426.
39. Panteghini, M., Bais, R., Serum enzymes. Burtis, C.A., Ashwood, E.R., Bruns, D.E., 5th ed, (eds.) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 2012, Elsevier Saunders, St. Louis.
40. Lilford, R.J., Bentham, L.M., Armstrong, M.J., Neuberger, J., Girling, A.J., What is the best strategy for investigating abnormal liver function tests in primary care? Implications from a prospective study. Br. Med. J. Open, 3, 2013, e003099.
41. Sturgeon, C.M., Duffy, M.J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D.W., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54 (2008), e11–e79.
42. Dolci, A., Scapellato, L., Panteghini, M., Appropriatezza delle richieste di PSA libero in un servizio di Medicina di Laboratorio ospedaliero. Biochim. Clin., 30, 2006, 362.
43. VanWagner, L.B., Green, R.M., Evaluating elevated bilirubin levels in asymptomatic adults. JAMA 313 (2015), 516–517.
44. Salinas, M., López-Garrigós, M., Lugo, J., Gutiérrez, M., Flors, L., Leiva-Salinas, C., Diagnostic accuracy of icteric index to detect abnormal total bilirubin values. J. Clin. Pathol. 65 (2012), 928–933.
45. Szoke, D., Braga, F., Valente, C., Panteghini, M., Measurement of icteric index as approach to detect abnormal total bilirubin values. J. Clin. Pathol. 66 (2013), 1095–1097.
46. Pasqualetti, S., Szőke, D., Panteghini, M., Suitability of icteric index (II) as front-line test for the identification of blood samples with abnormal total bilirubin (TB) concentrations. Biochim. Clin. 39 (2015), 270–274.
47. Panteghini, M., Procalcitonin: between evidence and critical issues. Biochim. Clin. 37 (2013), 12–14.
48. Procalcitonin testing for diagnosing and monitoring sepsis - NICE. Diagnostics guidance [DG18] Published: 7 October 2015. (available at) https://www.nice.org.uk/guidance/dg18 (Accessed December 2016).
49. Heyland, D.K., Johnson, A.P., Reynolds, S.C., Muscedere, J., Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit. Care Med. 39 (2011), 1792–1799.
50. Yealy, D.M., Fine, M.J., Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections?. JAMA 302 (2009), 1115–1116.
51. Vandijck, D.M., Depaemelaere, M., Labeau, S.O., Depuydt, P.O., Annemans, L., Buyle, F.M., et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int. J. Antimicrob. Agents 31 (2008), 161–165.
52. Bouadma, L., Luyt, C.E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375 (2010), 463–474.
53. Ng, V.L., Utilization management in the core laboratory. Clin. Chim. Acta 427 (2014), 154–157.
54. Pelloso, M., Basso, D., Padoan, A., Fogar, P., Plebani, M., Computer-based-limited and personalised education management maximise appropriateness of vitamin D, vitamin B12 and folate retesting. J. Clin. Pathol. 69 (2016), 777–783.
55. Lang, T., The Association for Clinical Biochemistry and Laboratory Medicine (ACB). National Minimum Re-Testing Interval Project. Prepared for the Clinical Practice Group of the ACB and Supported by the Royal College of Pathologists. (Available at:) http://www.acb.org.uk/docs/default-source/guidelines/acbmri-recommendations-a4-computer.pdf, 2013 (Accessed December 2016).
56. Morgen, E.K., Naugler, C., Inappropriate repeats of six common tests in a Canadian city: a population cohort study within a laboratory informatics framework. Am. J. Clin. Pathol. 144 (2015), 704–712.
57. Laxmisan, A., Vaughan-Sarrazin, M., Cram, P., Repeated hemoglobin A1C ordering in the VA health system. Am. J. Med. 124 (2011), 342–349.
58. Lee, J.-A., Zierler, B.K., The current state of practice in the diagnosis of venous thromboembolism at an academic medical center. Vasc. Endovasc. Surg. 45 (2011), 22–27.
59. Leaver, H., Lim, T.K., Thomson, P., Leaver, J., Choy, A.M.J., Lang, C.C., Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc. Ther. 27 (2009), 96–100.
60. McCall, S.J., Souers, R.J., Blond, B., Massie, L., Physician satisfaction with clinical laboratory services: a College of American Pathologists Q-Probes study of 81 institutions. Arch. Pathol. Lab. Med. 140 (2016), 1098–1103.
61. Plebani, M., Appropriateness in programs for continuous quality improvement in clinical laboratories. Clin. Chim. Acta 333 (2003), 131–139.